FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308385284> ?p ?o ?g. }

• W4308385284 abstract "<h3>Background</h3> Oncolytic viral therapies are thought to act through both direct killing of tumor cells and activation of conventional dendritic cells (cDCs), resulting in an enhanced T cell response. However, cDC activation has not been optimized with current therapies. MEM-288 is a conditionally-replicative oncolytic adenovirus encoding transgenes for human interferon beta (IFNβ) and a recombinant membrane-stable form of CD40-ligand (MEM40), two potent activators of the immune response and cDCs. <h3>Methods</h3> We evaluated intralesional adenoviral delivery of MEM40 and IFNβ to activate cDCs in mouse melanoma and lung tumor models. Flow cytometry and scRNA-seq were used to determine treatment impact on cDCs and T cells. Clinical translational research also investigated the immune response of intralesional administration of MEM-288 in patients with select solid tumors in an ongoing Phase 1 dose-escalation, multi-center, open-label trial (NCT05076760). Patient pre- and on-treatment tumor biopsies and peripheral blood were collected before and after MEM-288 treatment for immunologic evaluation. <h3>Results</h3> In preclinical studies, MEM40 and IFNβ in situ co-expression induced higher cDC activation than either molecule alone, in addition to a dramatic increase in lymph node migration, a systemic anti-tumor CD8⁺ T cell response, and regression of established tumors in a manner dependent upon type 1 cDCs. MEM40 and IFNβ expression enhanced generation of both Granzyme B⁺ CD8⁺ T cell effectors as well as TCF1⁺ stem-like CD8⁺ T cells that are known to be strongly associated with response to immune checkpoint inhibitors (ICIs). Intralesional therapy with MEM40 and IFNβ expressing adenovirus synergized with ICIs, leading to effective control of distant tumors and lung metastases. Notably, these preclinical results are translating into the clinical setting. Pre- and on-treatment biopsies from the initial 2 non-small cell lung cancer (NSCLC) patients on study were evaluated for TME impact of MEM-288 treatment. A single intralesional injection of low dose cohort MEM-288 (1e10 viral particles) resulted in shrinkage of the injected tumor (-31 and -53%), concomitant with substantial increases in overall CD8⁺ T cells and TCF1⁺ stem-like CD8⁺ T cells. Studies to determine systemic effects on T cells are ongoing. <h3>Conclusions</h3> MEM40 and IFNβ expression induces strong remodeling of the TME in both murine models and solid tumor patients. Preliminary safety, antitumor, and immune response data in the ongoing MEM-288 clinical trial is also encouraging. Following completion of the monotherapy study, an expansion arm is planned where MEM-288 will be combined with anti-PD1 antibody in patients with advanced NSCLC refractory to ICI. <h3>Ethics Approval</h3> The studies described received IRB approval (Moffitt: Adverra IRB, # Pro00060205, Duke: DUHS IRB, #Pro00109517) prior to commencement, and in the clinical trial described all participants gave informed consent before taking part." @default.
• W4308385284 created "2022-11-11" @default.
• W4308385284 creator A5001062982 @default.
• W4308385284 creator A5014639842 @default.
• W4308385284 creator A5015790093 @default.
• W4308385284 creator A5016680184 @default.
• W4308385284 creator A5018234323 @default.
• W4308385284 creator A5018642666 @default.
• W4308385284 creator A5028702225 @default.
• W4308385284 creator A5032171890 @default.
• W4308385284 creator A5039557924 @default.
• W4308385284 creator A5046273815 @default.
• W4308385284 creator A5050528758 @default.
• W4308385284 creator A5054228821 @default.
• W4308385284 creator A5058304111 @default.
• W4308385284 creator A5075077546 @default.
• W4308385284 creator A5079438136 @default.
• W4308385284 date "2022-11-01" @default.
• W4308385284 modified "2023-09-25" @default.
• W4308385284 title "1132 Impact of intralesional oncolytic viral therapy targeting<i>in situ</i>activation of CD40 and type 1 interferon signaling pathways on the TME and systemic T cell immunity in murine models and cancer patients" @default.
• W4308385284 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1132" @default.
• W4308385284 hasPublicationYear "2022" @default.
• W4308385284 type Work @default.
• W4308385284 citedByCount "0" @default.
• W4308385284 crossrefType "proceedings-article" @default.
• W4308385284 hasAuthorship W4308385284A5001062982 @default.
• W4308385284 hasAuthorship W4308385284A5014639842 @default.
• W4308385284 hasAuthorship W4308385284A5015790093 @default.
• W4308385284 hasAuthorship W4308385284A5016680184 @default.
• W4308385284 hasAuthorship W4308385284A5018234323 @default.
• W4308385284 hasAuthorship W4308385284A5018642666 @default.
• W4308385284 hasAuthorship W4308385284A5028702225 @default.
• W4308385284 hasAuthorship W4308385284A5032171890 @default.
• W4308385284 hasAuthorship W4308385284A5039557924 @default.
• W4308385284 hasAuthorship W4308385284A5046273815 @default.
• W4308385284 hasAuthorship W4308385284A5050528758 @default.
• W4308385284 hasAuthorship W4308385284A5054228821 @default.
• W4308385284 hasAuthorship W4308385284A5058304111 @default.
• W4308385284 hasAuthorship W4308385284A5075077546 @default.
• W4308385284 hasAuthorship W4308385284A5079438136 @default.
• W4308385284 hasBestOaLocation W43083852841 @default.
• W4308385284 hasConcept C154317977 @default.
• W4308385284 hasConcept C167672396 @default.
• W4308385284 hasConcept C183193105 @default.
• W4308385284 hasConcept C202751555 @default.
• W4308385284 hasConcept C203014093 @default.
• W4308385284 hasConcept C2776062744 @default.
• W4308385284 hasConcept C2776090121 @default.
• W4308385284 hasConcept C2777283488 @default.
• W4308385284 hasConcept C2777701055 @default.
• W4308385284 hasConcept C2780380082 @default.
• W4308385284 hasConcept C39347974 @default.
• W4308385284 hasConcept C502942594 @default.
• W4308385284 hasConcept C55493867 @default.
• W4308385284 hasConcept C71924100 @default.
• W4308385284 hasConcept C82210918 @default.
• W4308385284 hasConcept C86803240 @default.
• W4308385284 hasConcept C8891405 @default.
• W4308385284 hasConceptScore W4308385284C154317977 @default.
• W4308385284 hasConceptScore W4308385284C167672396 @default.
• W4308385284 hasConceptScore W4308385284C183193105 @default.
• W4308385284 hasConceptScore W4308385284C202751555 @default.
• W4308385284 hasConceptScore W4308385284C203014093 @default.
• W4308385284 hasConceptScore W4308385284C2776062744 @default.
• W4308385284 hasConceptScore W4308385284C2776090121 @default.
• W4308385284 hasConceptScore W4308385284C2777283488 @default.
• W4308385284 hasConceptScore W4308385284C2777701055 @default.
• W4308385284 hasConceptScore W4308385284C2780380082 @default.
• W4308385284 hasConceptScore W4308385284C39347974 @default.
• W4308385284 hasConceptScore W4308385284C502942594 @default.
• W4308385284 hasConceptScore W4308385284C55493867 @default.
• W4308385284 hasConceptScore W4308385284C71924100 @default.
• W4308385284 hasConceptScore W4308385284C82210918 @default.
• W4308385284 hasConceptScore W4308385284C86803240 @default.
• W4308385284 hasConceptScore W4308385284C8891405 @default.
• W4308385284 hasLocation W43083852841 @default.
• W4308385284 hasOpenAccess W4308385284 @default.
• W4308385284 hasPrimaryLocation W43083852841 @default.
• W4308385284 hasRelatedWork W1969504080 @default.
• W4308385284 hasRelatedWork W1983122232 @default.
• W4308385284 hasRelatedWork W2017949628 @default.
• W4308385284 hasRelatedWork W2058581379 @default.
• W4308385284 hasRelatedWork W2119058768 @default.
• W4308385284 hasRelatedWork W2618779717 @default.
• W4308385284 hasRelatedWork W4200379672 @default.
• W4308385284 hasRelatedWork W4286560817 @default.
• W4308385284 hasRelatedWork W4308385284 @default.
• W4308385284 hasRelatedWork W2741468361 @default.
• W4308385284 isParatext "false" @default.
• W4308385284 isRetracted "false" @default.
• W4308385284 workType "article" @default.